Jump to content

ALVAC-CEA vaccine

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by OAbot (talk | contribs) at 03:22, 2 August 2021 (Open access bot: doi added to citation with #oabot.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

ALVAC-CEA vaccine is a cancer vaccine containing a canary pox virus (ALVAC) combined with the carcinoembryonic antigen (CEA) human gene.

A phase I trial in 118 patients showed safety in humans.[1]

References

  1. ^ Kaufman, Howard L.; Lenz, Heinz-Josef; Marshall, John; Singh, Deepti; Garett, Chris; Cripps, Christine; Moore, Malcolm; von Mehren, Margaret; Dalfen, Richard; Heim, William J.; Conry, Robert M.; Urba, Walter J.; Benson, Al B.; Yu, Maria; Caterini, Judy; Kim-Schulze, Seunghee; Debenedette, Mark; Salha, Danielle; Vogel, Thorsten; Elias, Ileana; Berinstein, Neil L. (2008). "Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer". Clinical Cancer Research. 14 (15): 4843–4849. doi:10.1158/1078-0432.CCR-08-0276. PMID 18676757. S2CID 18152383.

Public Domain This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.


Stub icon

This oncology article is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=ALVAC-CEA_vaccine&oldid=1036682759"